Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
- PMID: 31484556
- PMCID: PMC6727581
- DOI: 10.1186/s40425-019-0718-6
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
Abstract
Background: Preclinical evidence suggests that low-dose radiation may overcome the inhibitory effects of the tumor stroma and improve a tumor's response to immunotherapy, when combined with high-dose radiation to another tumor. The aim of this study was to evaluate tumor responses to this combination in a clinical setting.
Methods: A post-hoc analysis of 3 ongoing immunoradiation trials was performed. Twenty-six (of 155) patients received low-dose radiation (1-20 Gy total), either as scatter from high-dose radiation or from intentional treatment of a second isocenter with low-dose radiation, were evaluated for response. The low-dose lesions were compared to lesions that received no radiation (< 1 Gy total). Response rates, both defined as complete and partial responses as defined by RECIST criteria were used to compare lesion types.
Results: The 26 patients had a total of 83 lesions for comparison (38 receiving low-dose, 45 receiving no-dose). The average dose given to low-dose lesions was 7.3 Gy (1.1-19.4 Gy), and the average time to response was 56 days. Twenty-two out of 38 (58%) low-dose lesions met the PR/CR criteria for RECIST compared with 8 out of 45 (18%) no-dose lesions (P = 0.0001). The median change for longest diameter size for low-dose lesions was - 38.5% compared to 8% in no-dose lesions (P < 0.0001). Among the low-dose lesions that had at least one no-dose lesion within the same patient as a control (33 and 45 lesions respectively), 12 low-dose lesions (36%) responded without a corresponding response in their no-dose lesions; Conversely, two (4%) of the no-dose lesions responded without a corresponding response in their low-dose lesion (P = 0.0004).
Conclusions: Low-dose radiation may increase systemic response rates of metastatic disease treated with high-dose radiation and immunotherapy.
Keywords: Abscopal effect; Immunotherapy; Low-dose radiotherapy; Metastatic cancer; Stereotactic ablative radiation therapy.
Conflict of interest statement
ICG, MA, JVH and DSH have received research grants from Bristol-Myers Squibb. JWW, ICG, JVH, and DSH also receive research funding from Merck. MA receives research funding from Novartis and Lilly. DSH and JWW are founders and have ownership interest in OncoResponse and MolecularMatch. All other authors declare no conflicts of interest. JWW reports research support from GlaxoSmithKline, Bristol Meyers Squibb, Merck , Nanobiotix, Mavu Pharma and Checkmate Pharmaceuticals. JWW serves on the scientific advisory board for RefleXion Medical, MolecularMatch, OncoResponse, CheckMate, Mavu Pharmaceuticals, Alpine Immune Sciences. He is co-founder of Healios Oncology, MolecularMatch, and OncoResponse and serves as an advisor to Astra Zeneca, Merck, MolecularMatch, Incyte, Aileron and Nanobiotix. JWW has the following patents; MP470 (amuvatinib), MRX34 regulation of PDL1, XRT technique to overcome immune resistance. MD Anderson Cancer Center has a trademark for RadScopalTM.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6727581/bin/40425_2019_718_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6727581/bin/40425_2019_718_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6727581/bin/40425_2019_718_Fig3_HTML.gif)
![Fig. 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6727581/bin/40425_2019_718_Fig4_HTML.gif)
Similar articles
-
Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.J Neurosurg. 2019 Feb 15;132(2):512-517. doi: 10.3171/2018.10.JNS181371. J Neurosurg. 2019. PMID: 30771783
-
Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.Radiat Oncol. 2019 Jan 28;14(1):18. doi: 10.1186/s13014-019-1222-3. Radiat Oncol. 2019. PMID: 30691492 Free PMC article.
-
Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials.Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):196-203. doi: 10.1016/j.ijrobp.2020.01.032. Epub 2020 Feb 7. Int J Radiat Oncol Biol Phys. 2020. PMID: 32036004 Clinical Trial.
-
Stereotactic Body Radiation Therapy for Spinal Metastases in the Postoperative Setting: A Secondary Analysis of Mature Phase 1-2 Trials.Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1405-1413. doi: 10.1016/j.ijrobp.2016.03.022. Epub 2016 Mar 25. Int J Radiat Oncol Biol Phys. 2016. PMID: 27209509 Review.
-
Immune modulation and stereotactic radiation: improving local and abscopal responses.Biomed Res Int. 2013;2013:658126. doi: 10.1155/2013/658126. Epub 2013 Nov 14. Biomed Res Int. 2013. PMID: 24324970 Free PMC article. Review.
Cited by
-
Combination of Radiation Therapy, Wim's Tumor 1 (WT1) Dendritic Cell Vaccine Therapy, and α-Galactosylceramide-Pulsed Dendritic Cell Vaccine Therapy for End-Stage Small Bowel Cancer.Cureus. 2024 Jul 20;16(7):e64972. doi: 10.7759/cureus.64972. eCollection 2024 Jul. Cureus. 2024. PMID: 39035592 Free PMC article.
-
Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy.Front Immunol. 2024 Mar 21;15:1360237. doi: 10.3389/fimmu.2024.1360237. eCollection 2024. Front Immunol. 2024. PMID: 38576617 Free PMC article. Review.
-
Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects.Front Immunol. 2024 Feb 21;15:1357101. doi: 10.3389/fimmu.2024.1357101. eCollection 2024. Front Immunol. 2024. PMID: 38449871 Free PMC article. Review.
-
Global research landscape and trends of cancer radiotherapy plus immunotherapy: A bibliometric analysis.Heliyon. 2024 Feb 27;10(5):e27103. doi: 10.1016/j.heliyon.2024.e27103. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38449655 Free PMC article.
-
A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma.Cancer Control. 2024 Jan-Dec;31:10732748241237331. doi: 10.1177/10732748241237331. Cancer Control. 2024. PMID: 38449377 Free PMC article. Clinical Trial.
References
-
- Barsoumian H, Cushman TR, Caetano MDS, Cadena A, Younes A, Tang C, et al. Low dose radiation improves anti-tumor responses in a phase 2 prospective trial of concurrent or sequential stereotactic radiation and Ipilimumab in patients with metastatic lesions. Int J Radiat Oncol Biol Phys. 2018;102(3):S26. doi: 10.1016/j.ijrobp.2018.06.149. - DOI
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous